IRCT20200825048515N75 IRCT 2024-10-25 Esfahan University of Medical Sciences Evaluation of laboratory findings and clinical outcome of addition of ascorbic acid in patients undergoing coronary artery bypass grafting Evaluation of laboratory findings and clinical outcome of addition of ascorbic acid in prime fluid in patients undergoing CABG 2024-12-21 anticipated 110 Complete https://irct.ir/trial/79716 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 110 eligible patients are randomly selected. For this, the letter A is written on 55 sheets, and the letter B is written on 55 sheets and each of them is placed in an envelope. Each patient is then asked to choose one of the envelopes. Depending on the selected envelope, the patient is assigned to one of two groups, Blinding description: In order to achieve the triple-blind study, different doses of ascorbic and placebo (normal saline) will be prepared daily by the operating room nurse (without the researcher's awareness) and placed in the bag and will be labeled A, B will be available to the circulation technician daily (Researcher) is placed. Therefore, the patient, the Investigator, the person recording the clinical and basic information of the patients as well as the statistical analyst will not be aware of the type of intervention. 3 Coronary artery bypass surgery. Intervention 1: Intervention group: 25 mg/kg of ascorbic acid will be added to the prime solution. Intervention 2: Control group: 25 mg/kg placebo (normal saline) will be added to the prime solution. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information